Evidence map›Paper›PMID 29717358›Full record

ArticleWorld journal of urology2018

Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer.

Marco Bandini, Michele Marchioni, Felix Preisser, Emanuele Zaffuto, Zhe Tian, Derya Tilki, Francesco Montorsi, Shahrokh F Shariat, Fred Saad, Alberto Briganti and 1 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in World journal of urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 4 countries.

Marco BandiniDivision of Oncology/Unit of Urology URI, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132, Milan, MI, Italy. marco.bandini.zoli@gmail.com.ORCID http://orcid.org/0000-0002-1462-1698
Michele MarchioniCancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.
Felix PreisserCancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.
Emanuele ZaffutoDivision of Oncology/Unit of Urology URI, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132, Milan, MI, Italy.
Zhe TianCancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.
Derya TilkiMartini Klinik, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Francesco MontorsiDivision of Oncology/Unit of Urology URI, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132, Milan, MI, Italy.
Shahrokh F ShariatDepartment of Urology, Medical University of Vienna, Vienna, Austria.
Fred SaadCancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.
Alberto BrigantiDivision of Oncology/Unit of Urology URI, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132, Milan, MI, Italy.
Pierre I KarakiewiczCancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.
Université de Montréal · CAVita-Salute San Raffaele University · ITUniversität Hamburg · DEMedical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNo prospective data examined the effect of radical prostatectomy (RP) vs. external beam radiotherapy (EBRT) in locally advanced prostate cancer (PCa). We aimed to compare survival outcomes of RP and EBRT in patients harboring cT3N0-1 PCa.

methodsWithin the SEER database (2004-2014), we identified 5500 cT3N0-1 PCa patients. Cumulative incidence plots and competing-risks regression models (CRRs) tested cancer-specific mortality (CSM) and other cause of mortality (OCM) according to treatment type. The multivariable relationship between baseline prostate-specific antigen (PSA) values and 10-year CSM after either RP or EBRT was graphically depicted using the LOESS smoothing method. Sensitivity analyses were performed in cT3N0-only patients, after OCM propensity score matching, and through landmark analyses.

resultsTen-year CSM and OCM rates were significantly higher after EBRT (15.8 and 28.2%) than RP (8.1 and 10.4%) (all p < 0.0001). In multivariable CRRs, RP yielded lower CSM [hazard ratio (HR): 0.64] than EBRT. Significantly lower 10-year CSM rate was recorded after RP vs. EBRT through the entire range of baseline PSA values. The same results were recorded in cT3N0 subgroup, as well as after OCM propensity score matching. Finally, landmark analyses at 6, 12, 24, and 36 months rejected the effect of favorable survival bias after RP.

conclusionsCSM was significantly lower after RP than EBRT in cT3N0-1 PCa. A lower CSM was recorded throughout the entire range of baseline PSA and even in cT3N0 subgroup, as well as after OCM propensity score matching and landmark analyses.

Indexed as

AgedCause of DeathDigital Rectal ExaminationHumansIncidenceMaleMiddle AgedPropensity ScoreProstatectomyProstatic NeoplasmsRadiotherapyRisk FactorsSEER ProgramSensitivity and SpecificitySurvival AnalysisTreatment OutcomeExternal beam radiotherapyLocally advanced diseaseProstate cancerRadical prostatectomySEER program

Identifiers

PMID29717358
OpenAlexW2800948643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.